Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Jaktinib Hydrochloride Tablets In The Treatment of Active Ankylosing Spondylitis (AS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04507659
Recruitment Status : Recruiting
First Posted : August 11, 2020
Last Update Posted : December 16, 2020
Sponsor:
Information provided by (Responsible Party):
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Brief Summary:
This trial uses a multi-center, randomized, double-blind, placebo, parallel-controlled design, and it is expected that about 105 cases will be enrolled in about 10 sites.

Condition or disease Intervention/treatment Phase
Ankylosing Spondylitis Drug: Jaktinib Hydrochloride Tablets Drug: Placebo Phase 2

Detailed Description:
The study is divided into two stages, the first stage (1-16 weeks) is the main study; the second stage (17-32 weeks) is the extended study. This study set up 3 groups:Jaktinib Hydrochloride Tablets 75mg Bid group, 100mg Bid group and a placebo control group. The subjects were randomly enrolled in the group 1:1:1.

Layout table for study information
Study Type : Interventional
Estimated Enrollment : 105 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multi-center, Randomized, Double-blind, Placebo, Parallel-controlled Phase Ⅱ Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Patients With Active Ankylosing Spondylitis
Actual Study Start Date : December 1, 2020
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : December 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Jaktinib 100mg
100 mg bid.po
Drug: Jaktinib Hydrochloride Tablets
Morning: 1*75mg simulated tablet, 2*50mg Jaktinib Hydrochloride Tablets; Evening: 1*75mg simulated tablet, 2*50mg Jaktinib Hydrochloride Tablets.

Active Comparator: Jaktinib 75mg
75 mg bid.po
Drug: Jaktinib Hydrochloride Tablets
Morning: 2*50mg simulated tablets and 1*75mg Jaktinib Hydrochloride Tablets; Evening: 2*50mg simulated tablets and 1*75mg Jaktinib Hydrochloride Tablets.

Placebo Comparator: Placebo
Placebo bid.po
Drug: Placebo
Morning: 1*75mg simulated tablet, 2*50mg simulated tablets; Evening: 1*75mg simulated tablet, 2*50mg simulated tablets.




Primary Outcome Measures :
  1. Assessment of Spondylo Arthritis International Society 20%(ASAS20) [ Time Frame: week 16 ]
    ASAS 20 response is a validated composite assessment, reflecting the proportion of treated patients who achieve within a defined time frame at least 20% improvement in score in at least 3 of a conventional set of 4 clinical domains relevant to AS and no worsening in the fourth domain.


Secondary Outcome Measures :
  1. Mean change from baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) [ Time Frame: week 2,4,8,12,16,20,24,32 ]
    It assess the disease activity. It was evaluated with a 6-question questionnaire. After taking the answer of each question out of 10, the total of the points was calculated by dividing the number of questions.The score range was 0-10, the low score meant that the spinal movement was better.

  2. Mean change from baseline in Bath ankylosing spondylitis functional index (BASFI) [ Time Frame: week 2,4,8,12,16,20,24,32 ]
    It assess functional status. It was evaluated with a 10-question questionnaire.The score range was 0-10, the low score meant that the spinal movement was better. After taking the answer of each question out of 10, the total of the points was calculated by dividing the number of questions.

  3. Mean change from baseline in Bath ankylosing spondylitis metrology index (BASMI) [ Time Frame: week 2,4,8,12,16,20,24,32 ]
    It characterises the spinal mobility of patients with ankylosing spondylitis. Cervical rotation, tragus-wall distance, lateral lumbar flexion, anterior lumbar flexion (modified schober), intermalleolar distance were measured. The score range was 0-10, the low score meant that the spinal movement was better.

  4. Mean change from baseline in Ankylosing spondylitis quality of life(ASQoL) [ Time Frame: week 2,4,8,12,16,20,24,32 ]
    It evaluates quality of life. Each statement on the ASQoL (18-item) is given a score of "1" or "0". A score of "1" is given where the item is affirmed, indicating adverse QoL. All item scores are summed to give a total score or index. Scores can range from 0 (good QoL) to 18 (poor QoL).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 18-65, both gender;
  • Active Ankylosing Spondylitis;
  • Patients who have been treated with non-steroidal anti-inflammatory drugs(NSAIDs) and still have active disease, or patients who are intolerant to NSAIDs and stop the drug;
  • Subjects receiving low-dose oral glucocorticoid therapy (≤10mg/d prednisone) should maintain a stable medication regimen for at least 4 weeks before the first dose of this study. Do not adjust the dose during the entire study period except in emergency situations.
  • Subjects receiving other non-prohibited co-drugs should maintain a stable medication regimen for at least 7 days before the first dose of this study;
  • Understand and voluntarily signed informed consent.

Exclusion Criteria:

  • A history of known or suspected complete spinal rigidity, or clinical and imaging confirmed complete spinal rigidity;
  • A history of any other autoimmune rheumatic disease;
  • Any history of joint prosthesis infection, and the prosthesis is still in place;
  • Those who are using strong opioid analgesics (such as methadone, hydromorphone, morphine, etc.);
  • Patients who have been treated with any JAK inhibitors (such as tofacitinib, baritinib, rocotinib, figatinib, upatinib, etc.);
  • People who have drug abuse or alcohol dependence;
  • People who have had herpes virus infection in the past month;
  • People who have a history of venous thrombosis (regardless of current treatment);
  • Any significant clinical and laboratory abnormalities that the investigator believes will affect the safety evaluator;
  • People who cannot be treated and followed up according to the trial protocol;
  • Any subject considered by the investigator to be unsuitable to participate in this clinical study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04507659


Contacts
Layout table for location contacts
Contact: Baochun De, MD 86-021-63284622 baochunde_1678@126.com

Locations
Layout table for location information
China, Shanghai
No.145 Shandong Zhong Lu Recruiting
Shanghai, Shanghai, China, 200011
Sponsors and Collaborators
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Investigators
Layout table for investigator information
Principal Investigator: Baochun De, MD RenJi Hospital
Layout table for additonal information
Responsible Party: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
ClinicalTrials.gov Identifier: NCT04507659    
Other Study ID Numbers: ZGJAK008
First Posted: August 11, 2020    Key Record Dates
Last Update Posted: December 16, 2020
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Suzhou Zelgen Biopharmaceuticals Co.,Ltd:
AS
Additional relevant MeSH terms:
Layout table for MeSH terms
Spondylitis
Spondylitis, Ankylosing
Bone Diseases, Infectious
Infection
Bone Diseases
Musculoskeletal Diseases
Spinal Diseases
Spondylarthropathies
Spondylarthritis
Ankylosis
Joint Diseases
Arthritis